9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901-Reference-Cited by-同舟云学术

9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901

Published:2004-09 Issue:5 Volume:22 Page:398-403
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Amin Asim,Halabi Susan,Gelmann Edward P.,Stadler Walter,Vogelzang Nicholas,Small Eric

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference26 articles.

1. Treatment of metastatic prostatic cancer with low-dose prednisone;Tannock;J Clin Oncol,1989

2. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer;Kantoff;J Clin Oncol,1999

3. A phase II study of docetaxel (taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer;Savarese;Semin Oncol,1999

4. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer;Kelly;J Clin Oncol,2001

5. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer;Scher;J Natl Cancer Inst,1999

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Second-Line Chemotherapy for Castration-Resistant Prostate Cancer;EMERG CANCER THER;2011

2. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models;Molecular Cancer Therapeutics;2008-07

3. Phase II study of rubitecan in recurrent or metastatic head and neck cancer;Cancer Chemotherapy and Pharmacology;2007-09-19

4. Docetaxel plus Prednisone versus Mitoxantrone plus Prednisone for Metastatic Hormone-Refractory Prostate Cancer in Chinese Patients: Experience of a Single Center;Urologia Internationalis;2007

5. Recent developments in the clinical activity of topoisomerase-1 inhibitors;Update on Cancer Therapeutics;2006-06